Navigation Links
Halozyme Therapeutics Reports First Quarter 2011 Financial Results
Date:5/6/2011

ts are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
ruhl@halozyme.comHalozyme Therapeutics, Inc.Condensed Consolidated Statements of OperationsQuarters Ended March 31,20112010(unaudited)(unaudited)REVENUES:Product sales

$
5,449$
397,810Revenues under collaborative agreements

7,378,4453,043,921Total revenues

7,543,8943,441,731OPERATING EXPENSES:Cost of product sales

11,7175,660Research and development

13,785,79711,467,204Selling, general and administrative

3,405,9663,757,013Total operating expenses

17,203,48015,229,877OPERATING LOSS

(9,659,586)(11,788,146)Interest and other income, net

23,869669NET LOSS

$
(9,635,717)$  (11,787,477)Basic and diluted net loss per share

$
(0.10)$
(0.13)Shares used in computing basic and dilutednet loss per share

100,927,40291,610,830Halozyme Therapeutics, Inc.Condensed Consolidated Balance SheetsMarch 31, December 31,20112010(unaudited)ASSETS Current assets:Cash and cash equivalents

$
73,829,299$
83,255,848Accounts receivable

1,731,3252,328,268Inventory.

248,474193,422Prepaid expenses and other assets.

3,382,9933,720,896Total current assets

79,19
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
2. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
3. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
4. Halozyme Receives $5.5 Million Payment From Baxter
5. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
6. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
9. Halozyme Therapeutics to Host Research Day for Investors and Analysts
10. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
11. Halozyme Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Dallas, Texas (PRWEB) , ... July 31, 2015 ... ... research report, offering competitive market analysis and premium industry insights on the global ... challenges, based on a collective study of vivid market scenarios and analysis of ...
(Date:7/31/2015)... ... 31, 2015 , ... R-Biopharm is proud to announce the ... in foods, has been accepted by AOAC International as Official First Action method. ... Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody to ...
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a ... Sales & Marketing Director. , With more than 25 years of experience ... reinforcing Tronics’ business development activities worldwide. He brings to the company his strong ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2
... (Nasdaq: CEPH ) announced today that Sarma P. ... President of Drug Delivery Technologies of CIMA LABS, Inc. ... the Cephalon drug delivery business at CIMA, its wholly owned ... http://www.newscom.com/cgi-bin/prnh/20090204/PH66729 )In his new role, Dr. Duddu will ...
... and ATLANTA, Feb 4 Lentigen Corporation, a ... of lentiviral gene delivery technologies, and Expression Therapeutics, ... today announced a collaborative agreement to co-develop novel ... is an inherited blood clotting disorder caused by ...
... Top Institute Pharma,(TI Pharma) has formed a consortium ... Nobilon, a subsidiary of Schering-Plough, to,develop a ,proof of ... reduce the rate of Chikungunya infections. , ... around the world in,recent decades. One of these diseases ...
Cached Biology Technology:Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 2Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 3Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 4Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 2Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 3Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership 2
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... amber by researchers at the University of Cologne, Germany ... genus of caddisfly, which has been named Palerasnitsynus . ... record of the living family Psychomyiidae in Burmese ... the fossil record. Burmese amber is 100 million years ...
... 2011 Reportlinker.com announces that a new market ... US Biologics  Market ... demand to exceed $100 billion by 2015 ... $100 billion in 2015, experiencing continuing strong growth ...
... Nottingham are developing microscopic organic medical imaging systems ... for currently incurable diseases and chronic life-threatening illnesses. ... the membrane of naturally occurring biological cells, could ... the potential to detect tumours earlier, monitoring electrical ...
Cached Biology News:US Biologics Market 2US Biologics Market 3US Biologics Market 4US Biologics Market 5US Biologics Market 6US Biologics Market 7Organic medical imaging system to detect disease and track medication 2
... Thermo's Wellwash AC is the easiest ... and is provided with liquid level ... bottles. The integrated orbital shaker and ... excellent washing performance. The big bottle ...
... Labsystems' Wellwash AC is the ... washer available, and is provided ... wash, waste and rinse bottles. ... automatic rinsing and priming functions ...
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... Rabbit polyclonal to MLF1 Interacting Protein/PBIP1 ... all tested applications). ... to amino acids 73-83 of Human ... Entrez Gene ID: 359815 ...
Biology Products: